相似文献
1
2
The case for adjuvant CMF chemotherapy in breast cancer. Has it been made?
Cancer Clin Trials. 1981 Winter;4(4):363-9.
3
Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Cancer. 2003 Jan 1;97(1):21-9. doi: 10.1002/cncr.10982.
4
5
Combination chemotherapy as an adjuvant treatment in operable breast cancer.
N Engl J Med. 1976 Feb 19;294(8):405-10. doi: 10.1056/NEJM197602192940801.
6
Combination chemotherapy for disseminated carcinoma of the breast.
Bol Asoc Med P R. 1975 Jun;67(6):157-63.
7
Surgery and adjuvant chemotherapy in the treatment of operable breast cancer.
Prog Clin Biol Res. 1977;12:391-404.
8
[CMF (cyclophosphamide, methotrexate, ftorafur) chemotherapy in advanced breast cancer].
Orv Hetil. 1983 Jan 9;124(2):79-84.
9
[Our experience with cyclophosphamide, methotrexate and 5-fluorouracil in the postoperative treatment of breast carcinoma].
Chir Ital. 1982 Apr;34(2):292-306.
10
Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Cancer. 2002 Jul 15;95(2):228-35. doi: 10.1002/cncr.10678.
Zotero 插件